Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Geeta Devgan"'
Autor:
Laura S. Wood, Dawn Conway, Maria Lapuente, George Salvador, Sheila Fernandez Gomez, Andrea Carroll Bullock, Geeta Devgan, Kathleen D. Burns
Publikováno v:
Journal of infusion nursing : the official publication of the Infusion Nurses Society. 45(3)
Immune checkpoint inhibitors, such as programmed cell death ligand 1 inhibitors pembrolizumab, nivolumab, atezolizumab, and avelumab, are used to treat patients with advanced urothelial carcinoma (UC). Based on data from the phase 3 JAVELIN Bladder 1
Autor:
Petros Grivas, Pedro C. Barata, Helen Moon, Thomas E. Hutson, Shilpa Gupta, Cora N. Sternberg, Vaidehi Dave, Chad Downey, Alicia C. Shillington, Geeta Devgan, Melissa Kirker, Sheena Thakkar, Howard M. Katzenstein, Abhijeet Bhanegaonkar, Frank Liu, Jason Brown, Guru P. Sonpavde
Publikováno v:
Journal of Clinical Oncology. 41:465-465
465 Background: The JAVELIN Bladder 100 clinical trial demonstrated a significant overall survival and progression-free survival benefit with avelumab 1LM + best supportive care (BSC) vs BSC alone for la/mUC not progressing on platinum-based chemothe
Autor:
Marc D. Chioda, Aimee-Lauren S Rosales, Jacob K Kettle, Mollie Reed, Geeta Devgan, Lindsey Parker
Publikováno v:
Advances in Therapy
Resistance to first- and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) and development and progression of central nervous system metastases remain significant issues in the treatment of ALK-positive non-small-ce
Autor:
Geeta Devgan, Adam Pluzanski, Maria Rita Migliorino, Rafael Rosell, Susan Quinn, Weiwei Tan, Jesus Corral, Kazuhiko Nakagawa, Yi-Long Wu, Tony Mok, R. Linke, Ki Hyeong Lee, Tao Wang
Publikováno v:
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
instname
Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the ARCHER 105
Autor:
Frank Liu, Halley Costantino, Chiemeka Ike, Shaloo Gupta, Abhijeet Bhanegaonkar, Sheena Thakkar, Geeta Devgan, Howard Katzenstein, Shilpa Gupta
Publikováno v:
Journal of Clinical Oncology. 40:4595-4595
4595 Background: The treatment (tx) landscape for la/mUC has evolved with the use of immunotherapy (IO) for platinum-refractory la/mUC as well as first-line (1L) maintenance therapy (1LM). This cross-sectional survey explored practice patterns for 1L
Autor:
Petros Grivas, Sumanta K. Pal, Jodi Smith, Cora N. Sternberg, Geeta Devgan, Srikala S. Sridhar, Joaquim Bellmunt, Arash Rezazadeh Kalebasty, Neeraj Agarwal
Although urothelial carcinoma (UC) is considered a chemotherapy-sensitive tumor, progression-free survival and overall survival (OS) are typically short following standard first-line (1L) platinum-containing chemotherapy in patients with locally adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7a778e8054bfcad62cc05c538b5a75a
http://hdl.handle.net/10230/48381
http://hdl.handle.net/10230/48381
Autor:
Frank Xiaoqing Liu, Jodi Smith, Ying Zheng, Saby George, John C White, Ruth Kim, Elizabeth J. Bell, Nicole M. Engel-Nitz, Geeta Devgan, Lincy S. Lal
Publikováno v:
The Oncologist
Background We investigated the association between adverse events (AEs) suspected to be immune‐related and health care resource utilization, costs, and mortality among patients receiving programmed cell death 1/programmed cell death ligand 1 immune
Autor:
Shilpa Gupta, Cathy Su, Abhijeet Bhanegaonkar, Shaloo Gupta, Sheena Thakkar, deMauri S Mackie, Geeta Devgan, Howard Katzenstein, Frank Liu
Publikováno v:
Journal of Clinical Oncology. 40:456-456
456 Background: The treatment landscape for la/mUC is evolving. Data on current real-world treatment trends in la/mUC are limited. This study assessed US physician treatment decision-making and prescribing patterns using qualitative interviews (QIs).
Autor:
Petros Grivas, Pedro C. Barata, Helen Moon, Thomas E. Hutson, Shilpa Gupta, Cora N. Sternberg, A. Simon Pickard, Vaidehi Dave, Natalia Han, Alicia C. Shillington, Geeta Devgan, Ruth Kim, Sheena Thakkar, Howard Katzenstein, Abhijeet Bhanegaonkar, Frank Liu, Guru P. Sonpavde
Publikováno v:
Journal of Clinical Oncology. 40:TPS578-TPS578
TPS578 Background: The randomized phase 3 JAVELIN Bladder 100 trial demonstrated overall and progression-free survival (OS and PFS) benefit with Ave 1LM for la/mUC not progressed with platinum-containing chemotherapy (PCT). PATRIOT II aims to underst
Publikováno v:
Future Oncology. 14:2103-2113
Avelumab is a human anti-PD-L1 checkpoint inhibitor with clinical activity in multiple solid tumors. Here, we describe the rationale and design for JAVELIN Ovarian 200 (NCT02580058), the first randomized Phase III trial to evaluate the role of checkp